Trials / Completed
CompletedNCT00093184
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI
A Study Evaluating the Safety and Efficacy of Bivalirudin in the Management of Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary PCI (BIAMI)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- The Medicines Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the benefit of bivalirudin in combination with clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications associated with early invasive management of patients presenting with an ST Elevation Myocardial Infarction (STEMI) and undergoing primary PCI, while providing similar rates of ischemic events when compared to published results of relevant trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Angiomax (bivalirudin) anticoagulant |
Timeline
- Start date
- 2004-04-01
- Completion
- 2005-12-01
- First posted
- 2004-10-07
- Last updated
- 2006-02-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00093184. Inclusion in this directory is not an endorsement.